NEWS HIGHLIGHTSMedia Articles Related to Dovonex (Calcipotriene Topical)
Weight Loss Might Ease Psoriasis, Study Hints
Source: MedicineNet Obesity (Weight Loss) Specialty [2013.05.30]
Title: Weight Loss Might Ease Psoriasis, Study Hints
Category: Health News
Created: 5/29/2013 4:35:00 PM
Last Editorial Review: 5/30/2013 12:00:00 AM
Diet May Ease Psoriasis Symptoms (CME/CE)
Source: MedPage Today Dermatology [2013.05.29]
(MedPage Today) -- Putting psoriasis patients on a low-calorie diet may improve quality of life and reduce psoriasis severity, researchers found.
Psoriasis
Source: MedicineNet Actinic Keratosis Specialty [2013.05.16]
Title: Psoriasis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/16/2013 12:00:00 AM
Scalp Psoriasis
Source: MedicineNet Hair Loss Specialty [2013.05.16]
Title: Scalp Psoriasis
Category: Diseases and Conditions
Created: 7/24/2012 3:21:00 PM
Last Editorial Review: 5/16/2013 12:00:00 AM
Kids With Psoriasis More Likely to Be Overweight: Study
Source: MedicineNet Psoriasis Specialty [2012.11.20]
Title: Kids With Psoriasis More Likely to Be Overweight: Study
Category: Health News
Created: 11/19/2012 4:36:00 PM
Last Editorial Review: 11/20/2012 12:00:00 AM
Published Studies Related to Dovonex (Calcipotriene Topical)
Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type
psoriasis: results of two multicenter, randomized, double-blind,
vehicle-controlled, phase III clinical trials. [2012]
plaque-type psoriasis... CONCLUSIONS: In two identically designed, phase III clinical trials,
A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. [2010.11]
The calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non-Hispanic. The aim of this study was to evaluate the efficacy and safety of the two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients...
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. [2010.11]
BACKGROUND: Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination. OBJECTIVE: We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone... CONCLUSION: This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. [2010.08]
The two-compound ointment (Taclonex/Daivobet/Dovobet ointment) combining calcipotriene 50 microg/g and betamethasone 0.5 mg/g (as dipropionate) is very effective in the treatment of psoriasis vulgaris... No patients using the two-compound ointment for all 52 weeks or alternating four-weekly with calcipotriene had HPA axis suppression.
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. [2010.07.02]
BACKGROUND: Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination. OBJECTIVE: We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone... CONCLUSION: This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Clinical Trials Related to Dovonex (Calcipotriene Topical)
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris [Completed]
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with:
1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8
weeks of calcipotriol cream
2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks
of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate)
ointment on weekends
3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks
of vehicle of calcipotriol cream
The objective is to compare the efficacy and safety of the different treatment regimens
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris [Recruiting]
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis [Completed]
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of
calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment
of calcipotriol scalp solution in patients with scalp psoriasis. The primary outcome is
patients with clear or minimal disease after 8 weeks treatment.
Further the occurrence of relapse and rebound after end of treatment in patients with clear
or minimal disease will be investigated.
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
The Role of Calcipotriol as Radioprotector of Skin [Not yet recruiting]
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo
cutaneous side effect in patients receiving radiotherapy to the breast.
To check the connection between the skin effect of radiotherapy and different parameters
including diseases such as diabetes and lupus, use of medications, allergies, weight,
habits, size of the irradiated breast, previous chemotherapy treatment and exposure to
sunlight.
|
